Senti Biosciences SNTI 深 滬
等待開盤 08-21 09:30:00 美东时间
0.436
-0.027
-5.83%
華盛通- 最 高0.4693
- 今 開0.4629
- 成交量 9.97万股
- 最 低 0.436
- 昨 收 0.463
- 總市值 1357.91万
- 52周最高 2.88
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 0.3331
- 委 比 98.99%
- 總股本 3114.48万
- 歷史最高 87.70
- 量 比 0.33
- 振 幅 7.19%
- 歷史最低 0.3331
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Senti Biosciences to spin off its gene-circuit pipeline
Senti Biosciences Holdings (SNTI) on Wednesday said privately held NewCo controlled by affiliates of top investor Celadon will acquire its gene-circuit pipeline, including SENTI-202. Equity holders ar...
07-15 19:59
Senti Biosciences Signs Agreement To Sell Assets Related To Its Gene-Circuit-Enabled Pipeline To Celadon For Up To $60M In Milestone Payments Over Seven Years
Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) ("SBH" or the "Company") today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial™ technology platform (the "Retained Assets") and unlock value for its Gene-Ci...
07-15 19:33
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.36) by 61.11 percent. This is a 90.07 percent increase over losses of $(1.41) per share from
05-14 20:46
Senti Biosciences Announces Completion Of Type B Initial Comprehensive Multidisciplinary RMAT Meeting With FDA Regarding SENTI-202, Logic Gated Off-The-Shelf CAR-NK Cell Therapy For R/R AML And Updated Phase 1 Clinical Data
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable
05-14 20:43
Senti Biosciences Enters Up To $40M Convertible Note Financing Agreement With Celadon Affiliate
Securities Purchase Agreement On April 27, 2026, Senti Biosciences Holdings, Inc. (the "Company"), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company ("Senti Holdings"), and Senti Biosciences,
05-02 04:11
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $13 to $11.
03-30 19:58
